Mayumi H, Himeno K, Tokuda N, Fan J L, Nomoto K
Immunobiology. 1987 May;174(3):274-91. doi: 10.1016/S0171-2985(87)80003-7.
In a fully allogeneic murine combination of C3H/HeSlc (C3H) (H-2k) and C57BL/6CrSlc (B6) (H-2b), C3H mice were primed i.v. with 1 X 10(8) spleen cells from B6 mice preimmunized i.v. with 5 X 10(7) C3H spleen cells and then were given i.p. 200 mg/kg cyclophosphamide (CP) 2 days later (Im-B6-Sc plus CP group). The tolerant state in those recipient mice was compared with that in mice made tolerant conventionally with 1 X 10(8) naive B6 spleen cells plus 200 mg/kg CP (naive-B6-Sc plus CP group). B6 skin was rejected in an almost normal fashion in both the naive-B6-Sc plus CP group and the Im-B6-Sc plus CP group. However, EL4 tumor allografts (B6 origin) inoculated after complete rejection of B6 skin grafts were specifically accepted in both groups. Moreover, the tumor growth in the Im-B6-Sc plus CP group was faster than that in the naive-B6-Sc plus CP group. Mixed lymphocyte reaction, cytotoxic T lymphocyte activity, and antibody production against the tolerogen were depressed more profoundly in the Im-B6-Sc plus CP group than in the naive-B6-Sc plus CP group. These observations were consistent with the results from tumor allografting. The other immunological parameters examined in the present study, including helper T cell activity and delayed foot-pad reaction, were retained in the Im-B6-Sc plus CP group at the same levels as in the naive-B6-Sc plus CP group. These observations were consistent with the results from skin allografting. In conclusion, tumor allograft tolerance was made more profound by the use of spleen cells from donors preimmunized with recipient antigens as the tolerogen than by the use of naive spleen cells. However, skin allograft tolerance was not achieved at all by these same treatments. The contribution of graft-versus-host disease to this phenomenon was excluded by the chimeric analysis in AKR/JSea (H-2k) mice given the preimmunized (with AKR antigens) B6 spleen cells plus CP. These results strongly support the existence of a less proliferative lymphocyte population which does not evoke cell divisions to mature even after the strong stimulation with the preimmunized spleen cells and is resistant to tolerance induction.
在C3H/HeSlc(C3H)(H-2k)和C57BL/6CrSlc(B6)(H-2b)的完全异基因小鼠组合中,给C3H小鼠静脉注射1×10⁸来自经静脉注射5×10⁷个C3H脾细胞预免疫的B6小鼠的脾细胞,然后在2天后腹腔注射200mg/kg环磷酰胺(CP)(免疫-B6-脾细胞加CP组)。将这些受体小鼠的耐受状态与用1×10⁸个未免疫的B6脾细胞加200mg/kg CP常规诱导耐受的小鼠(未免疫-B6-脾细胞加CP组)的耐受状态进行比较。在未免疫-B6-脾细胞加CP组和免疫-B6-脾细胞加CP组中,B6皮肤均以几乎正常的方式被排斥。然而,在B6皮肤移植完全排斥后接种的EL4肿瘤同种异体移植物(B6来源)在两组中均被特异性接受。此外,免疫-B6-脾细胞加CP组的肿瘤生长比未免疫-B6-脾细胞加CP组更快。与未免疫-B6-脾细胞加CP组相比,免疫-B6-脾细胞加CP组的混合淋巴细胞反应、细胞毒性T淋巴细胞活性以及针对耐受原的抗体产生受到的抑制更显著。这些观察结果与肿瘤同种异体移植的结果一致。本研究中检测的其他免疫参数,包括辅助性T细胞活性和迟发型足垫反应,在免疫-B6-脾细胞加CP组中保持与未免疫-B6-脾细胞加CP组相同的水平。这些观察结果与皮肤同种异体移植的结果一致。总之,与使用未免疫的脾细胞相比,使用经受体抗原预免疫的供体脾细胞作为耐受原可使肿瘤同种异体移植耐受更显著。然而,相同的处理根本无法实现皮肤同种异体移植耐受。通过对给予经(AKR抗原)预免疫的B6脾细胞加CP的AKR/JSea(H-2k)小鼠进行嵌合体分析,排除了移植物抗宿主病对这一现象的影响。这些结果有力地支持了存在一种增殖性较低的淋巴细胞群体,即使在用经预免疫的脾细胞强烈刺激后,该群体也不会引发细胞分裂以成熟,并且对耐受诱导具有抗性。